(Q37099985)

English

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

scientific article published on 07 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

phase III clinical trial

0 references

interferon gamma-1b

1 reference

based on heuristic

inferred from title

Mariusz Bidziński

5

object named as

Mariusz Bidzinski

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

David S. Alberts

1

object named as

David S Alberts

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

author name string

Christian Marth

2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Ronald D Alvarez

3

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Gary Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

David R Kardatzke

6

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Williamson Z Bradford

7

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Jeff Loutit

8

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

David H Kirn

9

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Mary C Clouser

10

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Maurie Markman

11

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

GRACES Clinical Trial Consortium

12

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

language of work or name

0 references

publication date

7 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

174-181

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Biologic and Immunologic Therapies for Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Interim analysis: the alpha spending function approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Designs for group sequential tests.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Interferon-gamma expression is an independent prognostic factor in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

The prognostic value of nuclear roundness and neopterin in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Regulatory T cells in ovarian cancer: biology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Interferon γ: a crucial role in the function of induced regulatory T cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.005

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.01.005

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37099985&oldid=2076555256"